一分钟看懂
这是一项关于癌的I 期 / II 期研究，登记的药物或干预包括Amivantamab；Pembrolizumab；Paclitaxel；Carboplatin，当前状态为招募中。登记地点显示中国北京、Cheng Du Shi、临沂、上海等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Amivantamab；Pembrolizumab；Paclitaxel；Carboplatin · I 期 / II 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁；另列出6项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出5项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Cancer Hospital of Peking University · 北京
- West China School of Medicine/West China Hospital, Sichuan University · Cheng Du Shi
- Linyi Cancer Hospital · 临沂
- Fudan Cancer Hospital · 上海
- Shanghai East Hospital · 上海
- Union Hospital Tongji Medical College of Huazhong University of Science and Technology · 武汉
公开的入选条件
- * Cohorts 1 to 5: Have histologically or cytologically confirmed recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that is considered incurable by local therapies or for Cohort 6: have histologically or cytologically confirmed locally adva
- * Participants in Cohorts 1, 2, 3B, 4 and 5 must have measurable disease according to RECIST version 1.1. Participants in Cohort 3A and Cohort 6 must have evaluable disease (defined as having at least 1 non-target lesion according to RECIST version 1.1.
- * Cohorts 1, 2, 3A, 3B, 4, and 5 only: Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less prior to the first dose of study treatment (except for alopecia or post-radiation skin changes \[any grade\], Gra
- * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- * Participant must have adequate organ and bone marrow function as follows, without history of red blood cell transfusion, platelet transfusion, or use of granulocyte colony-stimulating factor within 7 days prior to the date of the laboratory test.
- Participants should have: a) Hemoglobin \>=9 grams per deciliter (g/dL); b) Neutrophils \>=1.5 x 10\^3/mcg; c) Platelets \>=100 x 10\^3/mcg
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06385080；登记信息更新于 2026-09-25。